FDA requires NAION warning on labels of GLP-1 receptor agonist drugs in the US

According to ua.news, citing UPI, the US Food and Drug Administration (FDA) has required manufacturers of certain glucagon-like peptide-1 (GLP-1) receptor agonist drugs to add a warning to their labeling about a possible increased risk of non-arteritic anterior ischemic optic neuropathy (NAION) ua.newsua.newsua.newsOpen source ↗.

What NAION is

NAION is a rare eye condition that can cause vision deterioration in one eye and, in some cases, permanent vision loss. It is associated with reduced blood flow to the front part of the optic nerve.

The FDA lists sudden painless vision loss in one eye, which a person may notice after waking up, among the symptoms. Blurred vision or loss of part of the visual field are also possible, including blind spots or tunnel vision, color distortion, and reduced central visual acuity. People who notice such symptoms are advised to contact a healthcare professional. Risk factors may include smoking, diabetes, high blood pressure, sleep apnea, anemia, and kidney disease.

Which drugs are affected

GLP-1 receptor agonists mimic the action of a natural hormone released by the intestines. According to the FDA, this hormone helps control blood sugar levels after meals and affects areas of the brain that regulate appetite and eating behavior.

The drugs are used to treat type 2 diabetes, manage body weight, and for other purposes, including reducing the risk of serious cardiovascular events. FDA-approved drugs include Byetta, Victoza, Trulicity, Saxenda, Xultophy, Soliqua, Ozempic, Rybelsus, Wegovy, Mounjaro, Zepbound, and Foundayo.